ArticleBMJ paediatrics open2026
Midazolam as premedication for less invasive surfactant administration: a prospective single-centre audit.
Article in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLess invasive surfactant administration (LISA) is now a routinely practised method of administration of surfactant to neonates with respiratory distress. Many centres routinely use analgesia and/or sedation premedication prior to the LISA procedure; however, many different drugs are presently used, and the optimal premedication drug is unknown. We aimed to assess the efficacy and short-term safety of routine midazolam 50-100 µg/kg use as premedication for LISA.
methodsThis was a prospective single-centre audit of routine midazolam use as premedication before the LISA procedure over a 5.4-year period in a tertiary-level UK neonatal unit. We reviewed rates of procedural success, physiological stability and incidence of side effects as recorded contemporaneously on bespoke audit proformas following each LISA procedure. We also assessed numbers needing endotracheal intubation within 24 hours post the LISA procedure.
results120 neonates received midazolam premedication for LISA and had a completed proforma in the study period. In 119/120 (99.2%) cases, the procedure was deemed successful. Rates of side effects overall were: surfactant reflux n=22 (18.5%); bradycardia (heart rate <100/min) n=19 (16.0%); apnoea n=29 (24.4%); oxygen desaturation (SaO
conclusionsIn our experience, routine midazolam premedication for LISA was associated with relatively low rates of physiological instability and a high rate of procedural success. Midazolam is a worthy potential candidate for formal study in comparative trials with other LISA premedication drugs, and against non-pharmacological LISA administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.